Oxurion Announces Upcoming Presentation on THR-149 Phase 2 Clinical Trial (“KALAHARI”) at the Angiogenesis, Exudation, and Degeneration 2022 Conference
Oxurion NVLeuven, BELGIUM, Boston, MA, US – 11 February 2022 – 8.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical firm creating subsequent technology customary of care ophthalmic therapies, with a medical stage portfolio in vascular retinal problems, will probably be presenting knowledge from Half A of its two-part Part 2 Medical Trial … Read more